Market Overview

UPDATE: Stifel Nicolaus Initiates Medtronic at Hold on Valuation

Related MDT
Medtronics Reports FDA Approval Of Capsurefix Novus MRI Surescane 5076 Full-Body Scanners
Medtronic Announces Commencement of Pivotal Study of First Predictive Low Glucose Mgmt Technology for People with Diabetes
JPM Denies Report of Second Hack Attack (Fox Business)

Stifel Nicolaus initiated coverage on Medtronic (NYSE: MDT) with a Hold rating.

Stifel Nicolaus commented, "We are initiating coverage of Medtronic, Inc. (MDT) with a Hold rating on the shares. Fair-to-reasonable valuation for the stock and lack of dramatic upside drivers keep us on the sidelines for the moment. With approximately 50% of Medtronic's business still in pressured "no growth" markets (Cardiac Rhythm Management and Spine) and limited room for further operating margin expansion, we suspect Medtronic's 10.8x forward P/E multiple is unlikely to expand significantly on a relative basis. With MDT shares already trading at the high end of the industry peer group on an EV/EBITDA basis, we prefer to wait for a better entry point on the shares."

Medtronic closed at $41.10 on Monday.

Latest Ratings for MDT

DateFirmActionFromTo
Sep 2014NeedhamInitiates Coverage onBuy
Sep 2014Bank of AmericaReinstatesBuy
Sep 2014Sterne AgeeInitiates Coverage onNeutral

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters